The role of cannabis-based medicinal products (CBMPs) in managing osteoarthritis symptoms: a scoping review of current evidence and future directions.
| Journal | Clinical rheumatology |
| Study Type | Clinical Study |
| Population | Human participants |
Osteoarthritis affects over 32 million US adults, and current pharmacological options carry significant limitations including cardiovascular risks with NSAIDs and addiction potential with opioids. This scoping review synthesizes emerging evidence on cannabis-based medicines as a potentially safer alternative for OA symptom management.
This scoping review analyzed 19 studies from 517 initial results examining cannabis-based medicinal products for osteoarthritis symptoms. The review found preliminary evidence supporting CBD’s potential benefits for OA symptom relief, with topical formulations showing the most promising results and favorable safety profiles. However, the evidence quality is limited by significant variability in dosing protocols, product formulations, and study methodologies across the included trials.
“While I’m encouraged by the safety signal for topical CBD in OA, this review confirms what I see clinically—we still lack the dosing precision and product standardization needed for confident prescribing. The variability in formulations and dosing makes it difficult to translate these findings into consistent clinical protocols.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is the current evidence for using CBD products in osteoarthritis management?
Initial clinical studies suggest potential benefits for relieving osteoarthritis symptoms, with topical CBD formulations showing the most encouraging results. However, the overall strength of evidence remains limited due to considerable variability in CBD dosing, product types, and study methodologies across the 19 studies reviewed.
Which CBD formulation appears most effective for osteoarthritis pain?
Topical CBD formulations have demonstrated the most promising results for osteoarthritis symptom relief according to this scoping review. These topical applications also showed an acceptable safety profile compared to other CBD delivery methods.
Is CBD safe for osteoarthritis patients to use?
The available evidence suggests CBD has an acceptable safety profile, particularly when used topically for osteoarthritis. However, comprehensive long-term safety data remains limited due to the early stage of clinical research in this area.
What are the main limitations of current CBD osteoarthritis research?
The primary limitations include significant variability in CBD dosing protocols and product formulations across studies, making it difficult to establish standardized treatment recommendations. Additionally, the relatively small number of high-quality clinical trials limits the strength of current evidence.
Should I recommend CBD to my osteoarthritis patients based on this research?
While initial findings are encouraging, particularly for topical CBD, the evidence is still emerging and lacks standardization in dosing and formulations. Clinical decisions should be individualized, considering the acceptable safety profile while acknowledging the need for more robust clinical trial data to establish definitive treatment protocols.
